Efficacy and safety of add on Bempedoic acid on maximal dose of Rosuvastatin and Ezetimibe in patients with established coronary artery disease
Open accessIntegrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In two studies of patients with ASCVD on maximum dose rosuvastatin plus ezetimibe or rosuvastatin/atorvastatin plus ezetimibe, initiation of bempedoic acid achieved LDL-C reductions of 29.1% to 39.0% at 6 months.
“In these studies, the initiation of bempedoic acid achieved LDL-C reductions of 29.1% (baseline LDL-C = 100 mg/dL) to 39.0% (baseline LDL-C = 130 mg/dL) at 6 months’ follow-up [32,38].”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [38]
Real-world LDL-C reductions with bempedoic acid in secondary prevention populations ranged from 15% to 39%.
“These reductions were reported across both primary (23% to 39%) [24,29,44] and secondary prevention populations (15% to 39%) [25,32,38,39].”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [38]
LDL-C reductions with bempedoic acid added to statins ranged from 15% to 39%.
“Consistent effects were also seen when bempedoic acid was added to statins (15% to 39%) [25,30,32,38,39,44], and when used in statin intolerant patients (22% to 38%) [24,29,34,35,37,40,41], despite the latter group having higher baseline LDL-C.”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [38]
Cited by
Sorted by citations
Systematic literature review on the real-world effectiveness and safety of bempedoic acid
Cicero, A. F. G., Cannon, C. P., Gautam, R., Anwar, S., Ghatak, A., Sarnes, E., Powell, H. A., Chhabra, R., & Jawla, S. (2026) · Atherosclerosis Plus · doi:10.1016/j.athplu.2026.100562 · Cited by 1 · see citing works
- Authors
- Jaiswal, A., Garg, N., Kapoor, A., Tewari, S., Kumar, S., Khanna, R., Sahu, A., Khare, H., Katharia, A., & Arshad
- Affiliations
- Sanjay Gandhi Post Graduate Institute of Medical Sciences (IN)
- Venue
- Indian Heart Journal
- Publisher
- Elsevier BV
- Published
- 2024-12
- Volume
- 76
- Pages
- S109
- ISSN
- 0019-4832 (ISSN-L)
- OpenAlex
- W4405082174
- Cited by
- 0
- References
- 0
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Indian Heart Journal (publishedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- bempedoic acid, rosuvastatin, ezetimibe, adjunctive therapy, coronary artery disease, lipid-lowering therapy, LDL cholesterol lowering
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
